KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Depreciation & Amortization (CF): 2009-2024

Historic Depreciation & Amortization (CF) for Jazz Pharmaceuticals (JAZZ) over the last 16 years, with Dec 2024 value amounting to $32.8 million.

  • Jazz Pharmaceuticals' Depreciation & Amortization (CF) rose 27.05% to $9.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.7 million, marking a year-over-year increase of 35.08%. This contributed to the annual value of $32.8 million for FY2024, which is 7.70% up from last year.
  • Jazz Pharmaceuticals' Depreciation & Amortization (CF) amounted to $32.8 million in FY2024, which was up 7.70% from $30.4 million recorded in FY2023.
  • In the past 5 years, Jazz Pharmaceuticals' Depreciation & Amortization (CF) ranged from a high of $32.8 million in FY2024 and a low of $18.7 million during FY2020.
  • In the last 3 years, Jazz Pharmaceuticals' Depreciation & Amortization (CF) had a median value of $30.4 million in 2023 and averaged $31.2 million.
  • Data for Jazz Pharmaceuticals' Depreciation & Amortization (CF) shows a peak YoY skyrocketed of 43.06% (in 2021) over the last 5 years.
  • Over the past 5 years, Jazz Pharmaceuticals' Depreciation & Amortization (CF) (Yearly) stood at $18.7 million in 2020, then skyrocketed by 43.06% to $26.7 million in 2021, then increased by 13.43% to $30.3 million in 2022, then climbed by 0.36% to $30.4 million in 2023, then rose by 7.70% to $32.8 million in 2024.